Autonomic Nervous System Drugs Practice Questions

Q: What is the dose of Dopamine used for renal vasodilatation?

1-2 ug/kg/min. ### Explanation Dopamine is a unique catecholamine because its pharmacological effects are **dose-dependent**, targeting different receptors as the infusion rate increases. **1. Why Option D is Correct (1-2 µg/kg/min):** At low doses (typically **<2 µg/kg/min**), dopamine selectively acts on **D1 receptors** located in the renal, mesenteric, and coronary vascular beds. Activation of these receptors causes vasodilation, increasing renal blood flow and glomerular filtration rate (GFR). This is often referred to as the "renal dose," though its clinical utility in preventing acute kidney injury is now debated. **2. Analysis of Incorrect Options:** * **Option B (5-10 µg/kg/min):** At these intermediate doses, dopamine primarily stimulates **β1-adrenergic receptors** in the heart. This results in positive inotropic effects (increased contractility) and increased cardiac output. * **Option C (10-20 µg/kg/min):** At high doses, dopamine acts predominantly on **α1-adrenergic receptors**, leading to widespread vasoconstriction and increased peripheral vascular resistance. This is used to raise blood pressure in shock but may compromise renal perfusion. * **Option A (2.5 µg/kg/min):** While close to the threshold, standard textbooks and NEET-PG patterns traditionally define the "low/renal dose" range as **1-2 µg/kg/min**. **3. High-Yield Clinical Pearls for NEET-PG:** * **Receptor Sequence:** Remember the mnemonic **DBA** (Dopaminergic → Beta → Alpha) as the dose increases. * **Fenoldopam:** A selective D1 agonist used for hypertensive emergencies; it also maintains renal perfusion. * **Clinical Note:** Current ACLS guidelines emphasize that "renal dose" dopamine does not improve survival in renal failure; its primary use remains the management of symptomatic bradycardia or cardiogenic shock.

Q: Which drug inhibits the rate-limiting step of acetylcholine synthesis?

Hemicholinium. **Explanation:** The synthesis of Acetylcholine (ACh) occurs in the cholinergic nerve terminal [1], [5]. The **rate-limiting step** in this process is the **uptake of Choline** from the extracellular space into the neuron via a high-affinity sodium-dependent choline transporter (CHT1) [2], [4], [5]. * **Hemicholinium (Correct Answer):** This drug competitively inhibits the CHT1 transporter, blocking the entry of choline into the nerve terminal [3], [5]. Since choline availability is the bottleneck for synthesis, Hemicholinium effectively halts the production of new ACh [4]. **Analysis of Incorrect Options:** * **Vesamicol:** This drug inhibits the **VAT (Vesicle-Associated Transporter)** [5]. It prevents the storage of synthesized ACh into synaptic vesicles [3], but it does not affect the synthesis itself. * **Botulinum toxin:** This toxin acts on the presynaptic membrane to degrade **SNARE proteins** (like SNAP-25). This prevents the fusion of vesicles with the membrane, thereby inhibiting the **release** of ACh, not its synthesis [5]. * **Cocaine:** This drug primarily acts on the adrenergic system. It inhibits the **reuptake (Uptake-1)** of Norepinephrine (NE) from the synaptic cleft, prolonging its action. It has no direct role in ACh synthesis. **NEET-PG High-Yield Pearls:** * **Rate-limiting step of Catecholamine synthesis:** Tyrosine hydroxylase (inhibited by Metyrosine). * **Rate-limiting step of ACh synthesis:** Choline uptake (inhibited by Hemicholinium) [2]. * **Black Widow Spider Venom (Latrotoxin):** Causes massive, explosive release of ACh, leading to depletion. * **ACh Breakdown:** Unlike NE (which is mostly recycled via reuptake), ACh action is terminated primarily by enzymatic degradation via **Acetylcholinesterase (AChE)** in the synaptic cleft [2].

Q: Pralidoxime acts by?

Reactivating cholinesterase enzyme. ### Explanation **Correct Option: A. Reactivating cholinesterase enzyme** Pralidoxime (2-PAM) is a **cholinesterase reactivator** used in the treatment of organophosphate (OP) poisoning. Organophosphates inhibit the enzyme Acetylcholinesterase (AChE) by phosphorylating its esteratic site, leading to a toxic accumulation of acetylcholine. Pralidoxime has a high affinity for the phosphorus atom; it binds to the anionic site of the enzyme, nucleophilically attacks the phosphate group, and pulls it away. This releases the free, functional enzyme, allowing it to resume the breakdown of acetylcholine. **Why the other options are incorrect:** * **B & C:** Pralidoxime does not influence the genetic expression or cellular machinery required for the **synthesis** of enzymes or neurotransmitters. Its action is purely biochemical and focused on the existing inhibited enzyme. * **D:** Pralidoxime does not have significant agonist or antagonist activity at nicotinic or muscarinic receptors. Its clinical benefit is indirect, mediated through the restoration of endogenous enzyme activity. **High-Yield Clinical Pearls for NEET-PG:** * **The "Aging" Phenomenon:** Pralidoxime must be administered early. Once the enzyme-toxin bond undergoes "aging" (dealkylation), the bond becomes permanent, and oximes can no longer reactivate the enzyme. * **Blood-Brain Barrier:** Pralidoxime is a quaternary ammonium compound and **does not cross the BBB**. Therefore, it is ineffective against the central nervous system effects of OP poisoning (Atropine is required for CNS symptoms). * **Specific Utility:** It is highly effective at the **Neuromuscular Junction (NMJ)**, helping reverse skeletal muscle paralysis and fasciculations, which Atropine cannot do. * **Contraindication:** Oximes are generally avoided in **Carbamate poisoning**, as the enzyme-carbamate bond is reversible and oximes may paradoxically worsen the inhibition.

Q: What is the drug of choice in acute central anticholinergic syndrome?

Physostigmine. **Explanation:** **Central Anticholinergic Syndrome (CAS)** is caused by an overdose of drugs that cross the blood-brain barrier (BBB) and block muscarinic receptors (e.g., Atropine, Scopolamine, or Tricyclic Antidepressants). It presents with symptoms like delirium, hallucinations, and hyperthermia. **Why Physostigmine is the Drug of Choice:** Physostigmine is a **tertiary amine** acetylcholinesterase inhibitor. Unlike most other carbamates, its lipid solubility allows it to **cross the blood-brain barrier**. By inhibiting the breakdown of acetylcholine in the synaptic cleft, it increases the concentration of neurotransmitters both peripherally and centrally, effectively reversing the CNS toxicity of anticholinergic drugs. **Analysis of Incorrect Options:** * **A. Neostigmine:** This is a **quaternary ammonium** compound. It is polar and cannot cross the BBB; therefore, it can only reverse peripheral symptoms (like tachycardia) but is ineffective for central symptoms. * **C. Tacrine:** While it is a centrally acting anticholinesterase used in Alzheimer’s disease, it is not used for acute toxicity due to its significant hepatotoxicity and shorter duration of action compared to Physostigmine. * **D. 4-amino pyridine:** This is a potassium channel blocker used to improve walking in multiple sclerosis. It increases acetylcholine release but is not a standard treatment for CAS. **High-Yield Clinical Pearls for NEET-PG:** * **Physostigmine Antidote:** It is the specific antidote for **Belladonna/Atropine poisoning**. * **Contraindication:** Avoid Physostigmine in **TCA (Tricyclic Antidepressant) overdose** if there are QRS complexes widening on ECG, as it can worsen cardiac conduction delays and trigger seizures. * **Mnemonic:** Physostigmine **"P"**enetrates the CNS; Neostigmine **"N"**o (does not).

Q: Why is pyridostigmine preferred in the management of myasthenia gravis?

It has a longer duration of action than neostigmine.. **Explanation:** **1. Why Option B is Correct:** Pyridostigmine is the drug of choice for the long-term oral maintenance of Myasthenia Gravis (MG). The primary reason is its **pharmacokinetics**: it has a longer duration of action (3–6 hours) compared to neostigmine (2–4 hours). This allows for less frequent dosing, which is crucial for maintaining stable muscle strength throughout the day and improving patient compliance. Additionally, pyridostigmine has a more gradual onset and offset, leading to fewer "fluctuations" in muscle power. **2. Why Other Options are Incorrect:** * **Option A:** While it is true that pyridostigmine (a quaternary ammonium compound) does not cross the blood-brain barrier (BBB), this is **not** the reason it is preferred *over* neostigmine. Neostigmine is also a quaternary ammonium compound and also does not cross the BBB. * **Option C:** Incorrect. Both pyridostigmine and neostigmine are polar molecules and do not cross the BBB. If they did, they would cause unwanted central cholinergic side effects. * **Option D:** Incorrect. Pyridostigmine has a longer, not shorter, duration of action than neostigmine. **3. High-Yield NEET-PG Pearls:** * **Edrophonium (Tensilon Test):** Used for diagnosis of MG due to its very short duration (5–10 mins). * **Neostigmine:** Preferred for reversing neuromuscular blockade (post-surgery) and paralytic ileus due to its faster onset. * **Physostigmine:** The only clinically used anticholinesterase that **crosses the BBB** (tertiary amine); used as an antidote for Atropine poisoning. * **Cholinergic Crisis vs. Myasthenic Crisis:** If a patient's weakness worsens after an Edrophonium test, it is a Cholinergic Crisis (overdose); if it improves, it is a Myasthenic Crisis (underdose).

Q: D-Tubocurarine acts by?

Inhibiting nicotinic receptors at the myoneural junction. **Explanation:** **1. Why Option A is Correct:** D-Tubocurarine (d-TC) is the prototype **competitive (non-depolarizing) neuromuscular blocker**. It acts by reversibly binding to the **Nicotinic-M ($N_M$) receptors** located at the motor endplate of the myoneural (neuromuscular) junction. By competing with Acetylcholine (ACh) for these sites, it prevents endplate depolarization, leading to flaccid skeletal muscle paralysis. **2. Why the Other Options are Incorrect:** * **Option B:** While d-TC can block Nicotinic-G ($N_G$) receptors at autonomic ganglia in high doses (leading to hypotension), its primary therapeutic action and classification are based on its effect at the **myoneural junction**. * **Option C:** D-Tubocurarine produces a **non-depolarizing block**. Depolarizing blocks are characteristic of drugs like **Succinylcholine**, which act as agonists that cause persistent depolarization. * **Option D:** Inhibition of ACh re-uptake is not a mechanism of muscle relaxants. Hemicholinium is a drug that inhibits choline uptake, but d-TC acts post-synaptically. **3. High-Yield Clinical Pearls for NEET-PG:** * **Histamine Release:** d-TC is notorious for causing histamine release, which can lead to bronchospasm, hypotension, and urticaria. * **Reversibility:** The block produced by d-TC can be reversed by **Acetylcholinesterase inhibitors** (e.g., Neostigmine), which increase the concentration of ACh to outcompete the drug. * **Order of Paralysis:** Small, rapidly moving muscles (eyes, fingers) are paralyzed first; the **diaphragm** is the last to be affected and the first to recover. * **Hofmann Elimination:** Remember that **Atracurium and Cisatracurium** are preferred in organ failure as they undergo spontaneous degradation (Hofmann elimination), unlike d-TC.

Question 1

What is the dose of Dopamine used for renal vasodilatation?

Accepted Answer

1-2 ug/kg/min

Answer

2.5 ug/kg/min

Answer

5-10 ug/kg/min

Answer

10-20 ug/kg/min

Question 2

Which drug inhibits the rate-limiting step of acetylcholine synthesis?

Accepted Answer

Hemicholinium

Answer

Vesamicol

Answer

Botulinum toxin

Answer

Cocaine

Question 3

Pralidoxime acts by?

Accepted Answer

Reactivating cholinesterase enzyme

Answer

Promoting synthesis of cholinesterase

Answer

Promoting synthesis of acetylcholine

Answer

Direct action on cholinergic receptors

Question 4

Which drug is used as a truth serum?

Accepted Answer

Hyoscine

Answer

Glycopyrrolate

Answer

Solifenacin

Answer

Acetylcholine

Question 5

Dihydroergotamine differs from ergotamine in which of the following respects?

Accepted Answer

It is a more potent alpha-adrenergic blocker and less potent vasoconstrictor.

Answer

It is a more potent oxytocic.

Answer

It has antiemetic properties.

Answer

It has high oral bioavailability.

Question 6

What is the drug of choice in acute central anticholinergic syndrome?

Accepted Answer

Physostigmine

Answer

Neostigmine

Answer

Tacrine

Answer

4-amino pyridine

Question 7

Why is pyridostigmine preferred in the management of myasthenia gravis?

Accepted Answer

It has a longer duration of action than neostigmine.

Answer

It does not cross the blood-brain barrier.

Answer

It crosses the blood-brain barrier.

Answer

It has a shorter duration of action than neostigmine.

Question 8

Which of the following sympathetic receptors mediates both vasoconstriction and vasodilation?

Accepted Answer

Alpha 1 and Beta 2

Answer

Alpha 1 and Alpha 2

Answer

Alpha 1 and Beta 1

Answer

Beta 1 and Beta 2

Question 9

Which tissues are most sensitive to atropine?

Accepted Answer

The salivary, bronchial, and sweat glands

Answer

The gastric parietal cells

Answer

Smooth muscle and autonomic effectors

Answer

The heart

Question 10

D-Tubocurarine acts by?

Accepted Answer

Inhibiting nicotinic receptors at the myoneural junction

Answer

Inhibiting nicotinic receptors at the autonomic ganglion

Answer

Producing a depolarizing block

Answer

Inhibiting the re-uptake of acetylcholine

Autonomic Nervous System Drugs — MCQs

Autonomic Nervous System Drugs — MCQs

On this page

Practice by Chapter

Want unlimited practice?